National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials (PDQ®)
Patient Version   Health Professional Version
Last Modified: 3/18/2008  
Page Options
Print This Page
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

Denosumab May Help Prevent Bone Loss

Past Highlights
Related Links
Educational Materials About Clinical Trials

Clinical Trials: Questions and Answers

Questions to Ask Your Doctor

Drug Information from MedlinePlus
Finasteride in Preventing the Recurrence of Prostate Cancer

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information

Alternate Title

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Finasteride (Proscar) for the Chemoprevention of Prostate Cancer

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase III


Prevention


Completed


55 and over


NCI


SWOG-9217
PCPT-1, NCI-P93-0049

Trial Description

Purpose:

Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether finasteride is effective in preventing the recurrence of prostate cancer.

Randomized phase III trial to study the effectiveness of finasteride in preventing prostate cancer in patients who are at risk of recurrence.

Eligibility:

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will be randomly assigned to one of two groups. Patients in group one will receive finasteride. Patients in group two will receive a placebo.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Southwest Oncology Group

Ian Thompson, MD, Protocol chair
Ph: 210-567-5643
Email: thompsoni@uthscsa.edu

Back to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov